Spyre Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Spyre Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 62% to $886,000. Profit margin reached -38238%. Total operating expenses were $243,189,000.
Profit Margin
| 2014 | 0 | -10.34M | |
|---|---|---|---|
| 2015 | 6.08M | -11.29M | -185.62% |
| 2017 | 5.20M | -27.23M | -523.27% |
| 2019 | 0 | -78.25M | |
| 2020 | 0 | -80.89M | |
| 2021 | 18.73M | -65.80M | -351.14% |
| 2022 | 2.32M | -83.81M | -3598.75% |
| 2023 | 886K | -338.79M | -38238.15% |
SYRE Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue | 886K | 2.32M | 18.73M | 0 | 0 | 5.20M | 6.08M | 0 |
Cost of revenue | 964K | 1.96M | 2.00M | 1.62M | 901K | 0 | 89K | 19K |
Gross profit | -78K | 365K | 16.73M | -1.62M | -901K | 5.20M | 5.99M | -19K |
Operating exp. | ||||||||
Research and development | 89.50M | 58.57M | 57.06M | 59.63M | 64.59M | 22.81M | 11.45M | 6.83M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 243.18M | 87.11M | 84.38M | 81.48M | 79.43M | 32.63M | 17.4M | 8.88M |
Operating income | -242.30M | -84.78M | -65.64M | -81.48M | -80.33M | -27.67M | -11.31M | -8.90M |
Other income (expenses), net | -96.51M | -7K | -122K | 588K | 2.08M | 440K | 20K | -1.44M |
Income before tax | -338.81M | -83.95M | -65.66M | -80.89M | -78.25M | -27.23M | -11.29M | -10.34M |
Income tax expense | -26K | -136K | 141K | -593K | 0 | 0 | 0 | 0 |
Net income | -338.79M | -83.81M | -65.80M | -80.89M | -78.25M | -27.23M | -11.29M | -10.34M |
Earnings per share | ||||||||
Basic EPS | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -45.01 | -25.2 | -18.91 |
Diluted EPS | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -45.01 | -25.2 | -18.91 |
| Data source |